Implementation Facilitation to Promote Emergency Department–Initiated Buprenorphine for Opioid Use Disorder
D’Onofrio G, Edelman E, Hawk K, Chawarski M, Pantalon M, Owens P, Martel S, Rothman R, Saheed M, Schwartz R, Cowan E, Richardson L, Salsitz E, Lyons M, Freiermuth C, Wilder C, Whiteside L, Tsui J, Klein J, Coupet E, O’Connor P, Matthews A, Murphy S, Huntley K, Fiellin D. Implementation Facilitation to Promote Emergency Department–Initiated Buprenorphine for Opioid Use Disorder. JAMA Network Open 2023, 6: e235439. PMID: 37017967, PMCID: PMC10077107, DOI: 10.1001/jamanetworkopen.2023.5439.Peer-Reviewed Original ResearchConceptsOpioid use disorderRate of patientsOUD treatmentImplementation facilitationED visitsObservational cohortED cliniciansX-waiverUse disordersEmergency Department-Initiated BuprenorphineUntreated opioid use disorderEvaluation periodHybrid type 3Provision of buprenorphineBaseline periodGrand roundsRates of EDPrimary outcomeWhite patientsAcademic EDBlack patientsED patientsEmergency departmentCommunity cliniciansMAIN OUTCOMEHomelessness and Treatment Outcomes Among Black Adults With Opioid Use Disorder: A Secondary Analysis of X:BOT
Justen M, Scodes J, Pavlicova M, Choo T, Gopaldas M, Haeny A, Opara O, Rhee T, Rotrosen J, Nunes E, Hawk K, Edelman E. Homelessness and Treatment Outcomes Among Black Adults With Opioid Use Disorder: A Secondary Analysis of X:BOT. Journal Of Addiction Medicine 2023, 17: 463-467. PMID: 37579110, PMCID: PMC10323031, DOI: 10.1097/adm.0000000000001125.Peer-Reviewed Original ResearchConceptsClinical trialsTreatment outcomesSecondary analysisOpioid use disorder treatmentBlack individualsExtended-release naltrexoneOpioid use disorderAdditional clinical supportBlack participantsUse disorder treatmentBuprenorphine-naloxoneStudy medicationWeeks postrandomizationMedication initiationClinical characteristicsOpioid useTrial entryUrine toxicologyBlack patientsSedative useExtramedical useUse disordersClinical supportDisorder treatmentBlack adults